Valneva

Valneva FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Valneva (VLA.PA) as of Oct 9, 2026 is 49.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 683.12 % — a change of -92.71% (lower).

FCF Conversion

49.81 %

YoY

-92.71%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Valneva is 2025 49.81 % . FCF Conversion Rate (FCF/EBITDA) of Valneva was 2024 683.12 % . It decreases by -92.71% lower compared to the previous year.

The Valneva FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
402.42 EUR
Jan 1, 2019
307.05 EUR
Jan 1, 2020
-183.66 EUR
Jan 1, 2021
22.16 EUR
Jan 1, 2022
191.70 EUR
Jan 1, 2023
213.92 EUR
Jan 1, 2024
683.12 EUR
Jan 1, 2025
49.81 EUR
The Valneva FCF Conversion history
YEARFCF ConversionYoY
49.81 %-92.71%
683.12 %+219.34%
213.92 %+11.59%
191.70 %+765.12%
22.16 %-112.06%
-183.66 %-159.82%
307.05 %-23.70%
402.42 %-625.60%
-76.56 %+1,233.93%
-5.74 %-104.39%
130.86 %+84.03%
71.11 %—
Access this data via the Eulerpool API

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

FCF Conversion Rate (FCF/EBITDA) of Valneva is 49.81 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Valneva changed from 683.12 % to 49.81 %, representing a -92.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Valneva since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Valneva with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Valneva

All Key Metrics — Valneva